Alnylam (NASDAQ: ALNY) EVP trades 3,492 shares and receives equity awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ALNY’s EVP and Chief R&D officer Pushkal Garg reported a mix of stock sales and equity awards. On March 2, 2026, he received a stock option for 10,480 shares and 4,769 restricted stock units under Alnylam’s 2018 Stock Incentive Plan, with both awards vesting over time based on continued service.
On March 2 and 3, 2026, he conducted open-market sales totaling 3,492 common shares at prices generally in the $316–$332 range, some under a Rule 10b5-1 trading plan and some automatically sold to cover tax withholding on the equity awards. Footnotes also show 431 shares held via a 401(k) managed account and 250 shares held in a trust for which he disclaims beneficial ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 3,492 shares ($1,130,131)
Net Sell
18 txns
Insider
Garg Pushkal
Role
EVP Chief R&D
Sold
3,492 shs ($1.13M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 355 | $316.74 | $112K |
| Sale | Common Stock | 317 | $319.06 | $101K |
| Sale | Common Stock | 640 | $320.48 | $205K |
| Sale | Common Stock | 463 | $321.50 | $149K |
| Grant/Award | Stock Option (right to buy) | 10,480 | $0.00 | -- |
| Grant/Award | Common Stock | 4,769 | $0.00 | -- |
| Sale | Common Stock | 50 | $323.62 | $16K |
| Sale | Common Stock | 97 | $324.65 | $31K |
| Sale | Common Stock | 277 | $325.63 | $90K |
| Sale | Common Stock | 421 | $326.81 | $138K |
| Sale | Common Stock | 353 | $327.67 | $116K |
| Sale | Common Stock | 107 | $328.71 | $35K |
| Sale | Common Stock | 182 | $329.71 | $60K |
| Sale | Common Stock | 87 | $330.85 | $29K |
| Sale | Common Stock | 101 | $331.93 | $34K |
| Sale | Common Stock | 42 | $332.64 | $14K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 24,826 shares (Direct);
Stock Option (right to buy) — 10,480 shares (Direct);
Common Stock — 431 shares (Indirect, by Managed Account)
Footnotes (1)
- These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.16 to $324.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.20 to $325.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.21 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.23 to $327.23. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $327.24 to $328.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.28 to $329.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $329.29 to $330.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.30 to $331.30. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.32 to $332.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.34 to $332.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 20, 2025. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $316.45 to $317.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.71 to $319.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.97 to $320.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.30 to $321.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.
FAQ
What did Pushkal Garg report in the latest ALNY Form 4 filing?
Pushkal Garg reported a combination of equity grants and stock sales. He received stock options and restricted stock units, and sold several thousand Alnylam common shares in open-market transactions and automatic tax-withholding sales, all detailed with dates, share counts, and price ranges.
What new equity awards did Pushkal Garg receive from Alnylam (ALNY)?
Garg received a stock option covering 10,480 shares and 4,769 restricted stock units. The RSUs vest in three equal annual installments, and the option vests over four years, conditioned on his continued service with Alnylam Pharmaceuticals.
What is the Rule 10b5-1 trading plan mentioned in the ALNY Form 4?
The filing explains that certain sales were made under a Rule 10b5-1 trading plan adopted on November 20, 2025. Such plans pre-schedule trades, allowing insiders to sell shares under predetermined instructions, helping separate trading activity from day-to-day discretion.
What indirect Alnylam (ALNY) holdings are reported for Pushkal Garg?
The Form 4 lists 431 shares held through a 401(k) managed account and 250 shares held in a trust where his spouse is co-trustee. The filing states that Garg disclaims beneficial ownership of the trust shares.